loading page

Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia.
  • +4
  • Anne-Cécile Gauchy,
  • Maxime Hentzien,
  • Alain Wynckel,
  • Victoire De Marcellus,
  • Cyrielle Rodier,
  • Alain Delmer,
  • Anne Quinquenel
Anne-Cécile Gauchy
Hopital Robert Debré
Author Profile
Maxime Hentzien
Hopital Robert Debré
Author Profile
Alain Wynckel
Hôpital Maison Blanche
Author Profile
Victoire De Marcellus
Hopital Robert Debré
Author Profile
Cyrielle Rodier
Hopital Robert Debré
Author Profile
Alain Delmer
Hopital Robert Debré
Author Profile
Anne Quinquenel
Hopital Robert Debré
Author Profile

Abstract

We report a case of refractory life-threatening warm autoimmune hemolytic anemia (wAIHA) associated with chronic myelomonocytic leukemia (CMML) for which all conventional treatments had failed. The use of eculizumab allowed controlling hemolysis and resulted in transfusion independence. These data support the use of eculizumab in refractory wAIHA.

Peer review status:ACCEPTED

14 Apr 2020Submitted to Clinical Case Reports
20 Apr 2020Submission Checks Completed
20 Apr 2020Assigned to Editor
29 Apr 2020Reviewer(s) Assigned
10 Jun 2020Review(s) Completed, Editorial Evaluation Pending
04 Jul 20201st Revision Received
04 Jul 2020Submission Checks Completed
04 Jul 2020Assigned to Editor
10 Jul 2020Review(s) Completed, Editorial Evaluation Pending
12 Jul 2020Reviewer(s) Assigned
21 Jul 2020Editorial Decision: Accept